“

The utility of the PARP inhibitors could be much broader than just patients that have a tumor with the BRCA mutation, that becomes relevant when you start thinking about the drugs' role in other tumor types like prostate cancer and breast cancer where the incidence of new patients each year is much greater than in ovarian cancer.